We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Arrowhead Pharmaceuticals Inc (ARWR) Common Stock USD0.001

Sell:$66.89 Buy:$66.94 Change: $0.14 (0.21%)
Market closed |  Prices as at close on 21 October 2021 | Switch to live prices |
Sell:$66.89
Buy:$66.94
Change: $0.14 (0.21%)
Market closed |  Prices as at close on 21 October 2021 | Switch to live prices |
Sell:$66.89
Buy:$66.94
Change: $0.14 (0.21%)
Market closed |  Prices as at close on 21 October 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company uses a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's pipeline includes ARO-APOC3 for hypertriglyceridemia, ARO-ANG3 for dyslipidemia, ARO-HSD for liver disease, ARO-ENaC for cystic fibrosis, ARO-HIF2 for renal cell carcinoma, ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-LUNG2 for chronic obstructive pulmonary disorder, and ARO-COV for the coronavirus that causes COVID-19 and other possible future pulmonary-borne pathogens.

Contact details

Address:
177 E Colorado Blvd, Suite 700
PASADENA
91105
United States
Telephone:
+1 (626) 6964702
Website:
arrowheadpharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ARWR
ISIN:
US04280A1007
Market cap:
$6.99 billion
Shares in issue:
104.26 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Douglass Given
    Chairman of the Board
  • Christopher Anzalone
    President, Chief Executive Officer, Director
  • Kenneth Myszkowski
    Chief Financial Officer
  • James Hamilton
    Senior Vice President, Discovery & Translational Medicine
  • Curt Bradshaw
    Chief Scientific Officer
  • Patrick O'Brien
    Chief Compliance Officer, General Counsel, Company Secretary
  • Javier San Martin
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.